Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
67.51
+0.02 (0.03%)
After Hours: 67.64 +0.13 (0.19%)
Mar 24, 6:52PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 67.20 - 67.87
52 week 65.38 - 103.10
Open 67.57
Vol / Avg. 6.04M/10.39M
Mkt cap 87.80B
P/E 6.79
Div/yield 0.52/3.08
EPS 9.94
Shares 1.31B
Beta 1.15
Inst. own 78%
Jan 31, 2017
Q4 2016 Gilead Sciences Inc Earnings Release (Estimated)
Jan 9, 2017
Gilead Sciences Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 42.34% 44.38%
Operating margin 55.26% 58.02%
EBITD margin - 64.57%
Return on average assets 21.89% 24.82%
Return on average equity 69.73% 72.16%
Employees 9,000 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Officers and directors

John C. Martin Ph.D. Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Kevin B. Young CBE Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Kathleen Watson Executive Vice President - Human Resources
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James R. Meyers Executive Vice President - Worldwide Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Martin Silverstein M.D. Executive Vice President - Strategy
Age: 48
Bio & Compensation  - Reuters
John F. Cogan Jr. Ph.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters